Form 4: Fulgent Genetics' Chief Scientific Officer Reports Stock Transactions Following Vesting of Restricted Stock Units

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units, along with shares withheld for tax obligations.

Summary

• On February 25th and 26th, 2025, Hanlin Gao, the Chief Scientific Officer of Fulgent Genetics, engaged in transactions involving the company's common stock.
• These transactions included the acquisition of shares through the vesting of performance-based restricted stock units granted on February 28, 2022, February 23, 2023, and February 26, 2024.
• Additionally, shares were acquired through restricted stock units vesting over three years, starting March 1, 2025.
• A portion of the shares were disposed of to satisfy tax withholding obligations related to the vesting of these restricted stock units.
• The price per share for the shares withheld for taxes was $16.29 on February 25th and $16.24 on February 26th.
• Following these transactions, Gao directly owns 965,295 shares of Fulgent Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine stock transactions related to executive compensation. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The vesting of restricted stock units suggests that performance milestones were met, which could be viewed positively.
• Continued vesting of restricted stock units indicates ongoing alignment of the executive's interests with the company's long-term performance.

Future Outlook

The reporting person will continue to vest in restricted stock units over the next three years, subject to continued service.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates the normal course of compensation and does not necessarily reflect a change in the executive's outlook on the company.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation mechanisms.
• The vesting of restricted stock units aligns the executive's interests with those of shareholders.

Next Steps

• The reporting person will continue to vest in restricted stock units quarterly over the next two years, subject to continued service.

Key Dates